AMXI 3001
Alternative Names: AMXI-3001Latest Information Update: 28 Sep 2024
At a glance
- Originator AtlasMedx
- Class Antineoplastics; Small molecules
- Mechanism of Action Bcr-Abl tyrosine kinase inhibitors; Poly(ADP-ribose) polymerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Cancer in USA
- 09 Mar 2021 AMXI 3001 is available for licensing as of 12 Aug 2020. https://atlasmedx.com/partnering/